Generic Name and Formulations:
Imiglucerase 200 Units, 400 Units; per vial; pwd; for IV infusion after reconstitution.
Sanofi Genzyme Company
Indications for CEREZYME:
For long-term enzyme replacement therapy in patients with confirmed Type 1 Gaucher disease that results in one or more of the following conditions: 1) anemia; 2) thrombocytopenia; 3) bone disease; 4) hepatomegaly or splenomegaly.
Adults and Children:
<2yrs: not recommended. ≥2yrs: Give by IV infusion over 1–2 hours. Individualize. Initial dose range: 2.5 Units/kg 3 times a week to 60 Units/kg once every 2 weeks.
Monitor periodically for IgG antibody formation during the first year. Patients previously treated with Ceredase (alglucerase inj) who have developed antibody or hypersensitivity to Ceredase. Monitor for pulmonary hypertension, pneumonia. Pregnancy (Cat.C). Nursing mothers.
GI upset, abdominal pain, rash, pruritus, fatigue, headache, fever, dizziness, chills, backache, tachycardia, inj site reactions, hypersensitivity. Also children: dyspnea, flushing, coughing,
Sign Up for Free e-newsletters
- Managing Chemo Brain in Pediatric Survivors of Childhood Cancer
- Aggressive Therapy Provides No Additional Advantage in Metastatic Prostate Cancer
- Excretion of Volatile Organic Compounds Higher in AYAs Using Vaping Products
- FDA, ASHP Actions to Prevent or Manage Chemotherapy Drug Shortages
- Breast Cancer Screening Recommendations Not Completely Reflective of Race, Age
- Various Aspects of Palliative Care Focus Associated With Different Outcomes In Cancer
- Cost vs Benefits: The Controversy Over Proton Beam Radiotherapy
- Patient Expectations at Odds With Actual Outcomes for Radiotherapy in Breast Cancer
- Patients Desire More Online Tools and Access
- Metformin Plus Ruxolitinib: A Potential Therapeutic Alternative for Myeloproliferative Neoplasms
- Sexual Quality of Life Decreased During, After Chemotherapy for Digestive Cancers
- CHEMO-SUPPORT: A Nursing Intervention to Relieve Chemotherapy Symptom Burden
- Approach and Management of Checkpoint Inhibitor-related Immune Hepatitis
- Revised AJCC8 Demonstrates Superior Tumor Classification for HNCSCC
- Oral Androgen Receptor Inhibitor Granted FDA Approval for Nonmetastatic CRPC
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|